Sendero Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-20,944
| Closed | -$2.86M | – | 190 |
|
|
2024
Q4 | $2.86M | Buy |
20,944
+672
| +3% | +$91.7K | 0.43% | 50 |
|
|
2024
Q3 | $2.34M | Buy |
20,272
+537
| +3% | +$61.9K | 0.37% | 49 |
|
|
2024
Q2 | $2.72M | Buy |
19,735
+172
| +0.9% | +$23.7K | 0.46% | 45 |
|
|
2024
Q1 | $2.7M | Sell |
19,563
-254
| -1% | -$35K | 0.46% | 46 |
|
|
2023
Q4 | $2.61M | Buy |
19,817
+271
| +1% | +$35.7K | 0.49% | 44 |
|
|
2023
Q3 | $2.2M | Buy |
19,546
+4,899
| +33% | +$551K | 0.47% | 45 |
|
|
2023
Q2 | $1.38M | Sell |
14,647
-1,527
| -9% | -$144K | 0.3% | 65 |
|
|
2023
Q1 | $1.64M | Buy |
16,174
+1,308
| +9% | +$132K | 0.5% | 47 |
|
|
2022
Q4 | $1.78M | Buy |
14,866
+1,257
| +9% | +$150K | 0.63% | 28 |
|
|
2022
Q3 | $1.45M | Buy |
13,609
+755
| +6% | +$80.2K | 0.6% | 23 |
|
|
2022
Q2 | $1.25M | Buy |
12,854
+1,756
| +16% | +$171K | 1.2% | 23 |
|
|
2022
Q1 | $1.04M | Sell |
11,098
-151
| -1% | -$14.2K | 0.48% | 28 |
|
|
2021
Q4 | $958K | Buy |
+11,249
| New | +$958K | 0.43% | 37 |
|